Compare KBDC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KBDC | ACHV |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 822.8M | 726.5M |
| IPO Year | 2018 | 2018 |
| Metric | KBDC | ACHV |
|---|---|---|
| Price | $13.00 | $6.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $14.50 | $14.15 |
| AVG Volume (30 Days) | 398.5K | ★ 1.3M |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | ★ 12.31% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.14 | $2.62 |
| 52 Week High | $15.87 | $8.64 |
| Indicator | KBDC | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 53.25 | 45.21 |
| Support Level | $12.88 | $5.96 |
| Resistance Level | $13.65 | $7.30 |
| Average True Range (ATR) | 0.28 | 0.40 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 76.00 | 47.66 |
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.